Milestone Q2 net loss $9.4M; FDA acceptance of CARDAMYST NDA with PDUFA March 2025

Milestone Pharmaceuticals Inc.

2024-Q2 EPS reported -$0.34

FDA accepted CARDAMYST (etripamil) NDA for PSVT; PDUFA target date set for March 2025.
Cash and equivalents $83.3M as of June 30, 2024, expected to fund operations into 2026.
Q2 2024 net loss $9.4M vs $16.0M in Q2 2023; R&D expenses down to $2.8M from $8.6M.
Stuart Duty and Andrew Saik appointed as independent directors to the board.
Phase 3 AFib-RVR trial design ongoing; enrollment planned for first half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.